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Summary
The purpose of the present work is to evaluate the efficacy of an approach that combines 
clinical history, skin tests results, and premedication, in preventing recurrent hypersensitivity 
reactions to iodinated contrast media (ICM). Skin Prick tests, Intradermal tests, and Patch 
tests were performed in 36 patients with a previous reaction to ICM. All patients underwent 
a second contrast enhanced radiological procedure with an alternative ICM selected on the 
basis of the proposed approach. After alternative ICM re-injection, only one patient presented 
a mild NIR. The proposed algorithm, validated in clinical settings where repeated radiological 
exams are needed, offers a safe and practical approach for protecting patients from recurrent 
hypersensitivity reactions to ICM. 
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Proposal of a skin tests based approach  
for the prevention of recurrent hypersensitivity 
reactions to iodinated contrast media
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M.g. SaBBaDini1,2, S. Voltolini3, g. coloMBo2
Introduction
The incidence of hypersensitivity reactions to iodinated contrast 
media (ICM) has grown dramatically in recent years, together 
with the tremendous increase of ICM administration (1). At 
present, ICM are among the most frequently used pharmaceu-
ticals for intravascular injection with over 75 million infusions 
per year worldwide (2,3). 
According to the timing of onset, hypersensitivity reactions have 
been classified in immediate (IRs) and non-immediate reactions 
(NIRs). Immediate reactions occur within one hour after con-
trast administration; non-immediate reactions occur more than 
one hour after injection (4). Interestingly, at least for IRs, chem-
ical structure, osmolarity and iodine content of the different 
ICM have been shown to influence the likelihood of develop-
ing a hypersensitivity reaction. For instance, high-osmolar ICM 
are not used any more, due to a higher risk of adverse events 
(4,5), while low-osmolar ICM are routinely used and regarded 
as relatively safe, with an overall frequency of adverse reactions 
that ranges from 0.7 to 3.1% (4). Low-osmolar ICM can be 
further distinguished into non-ionic monomers (iohexol, iopa-
midol, ioversol, iopromide, iomeprol, iopentol and iobitridol), 
ionic dimers (ioxaglate), and non-ionic dimers (iodixanol), with 
monomeric ICM being more frequently involved in IRs, and 
dimeric ICM in NIRs (6,7).
From a pathogenic perspective, ICM hypersensitivity reactions 
have traditionally been classified as non-allergic reactions, since 
(i) reaction on first exposure can occur, and (ii) contrast me-
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urticaria and angio-oedema (grade 1); mild systemic reactions 
including skin manifestations, abdominal symptoms, respirato-
ry symptoms, cardiovascular symptoms (tachycardia) (grade 2); 
life-threatening systemic reactions including shock (grade 3); 
cardiac and/or respiratory arrest (grade 4) (20). Non-immediate 
reactions were defined as mild when no treatment was required, 
moderate when the patient responded readily to an appropriate 
treatment without hospitalization, and severe when the reaction 
required treatment in hospital, was life-threatening or resulted 
in death (4). All subjects signed written, informed consent for 
the investigations described. Since all tests were performed for 
diagnostic purposes, an ethical committee approval was not re-
quired for this observational analysis.
Skin testing. All patients were evaluated within 2 to 6 months 
after the adverse reaction and were tested with a panel of at least 
3 ICM used at the Radiology Department of our Institutes in 
addition to the culprit agent, when known. The panel of ICM 
included: iohexol (Omnipaqueâ 300 mg I/mL), iomeprol (Io-
meronâ 400 mg I/mL), iopromide (Ultravistâ 370 mg I/mL), 
iodixanol (Visipaqueâ 270 mg I/mL), iobitridol (Xenetixâ 300 
mg I/mL). Skin prick tests with undiluted ICM, IDTs with 
100-fold diluted, 10-fold diluted, and undiluted ICM, and PTs 
with undiluted ICM were performed, and interpreted according 
to the International Guidelines and the European multicenter 
study protocol respectively (15,21).  
Algorithm for the selection of alternative iodinated contrast media. 
Alternative ICM for subsequent radiological procedures were 
chosen according to an algorithm based on skin tests results and 
patient history, proposed in figure 1: (i) avoidance of the pre-
vious culprit ICM, when known, was mandatory, even in pres-
ence of negative skin tests for that compound; (ii) contrast me-
dia with positive results on skin tests were avoided as well; (iii) 
in the absence of positive skin tests and/or known culprit ICM, 
non-ionic dimeric ICM were preferred over monomeric ICM, 
because the former are typically less implicated in immediate life 
threatening reactions (6,7); (iv) in the presence of positive skin 
tests for all the tested ICM, especially when prior hypersensitiv-
ity reaction was severe, iodinated contrast enhanced exam was 
discouraged, and a possible alternative procedure was suggested.
Premedication. Premedication was adopted in all patients with a 
previous history of hypersensitivity to ICM undergoing a new 
radiological examination, regardless the entity of the initial re-
action. Premedication was performed according to a protocol 
approved and adopted by the American College of Radiology 
for the last 5 years: Methylprednisolone (Medrol®) 32 mg by 
mouth 12 hours and 2 hours before ICM injection, and Hy-
droxyzine Hydrochloride (Atarax®) 25 mg by mouth 1 hour 
before ICM injection (22). Intensive care unit doctor assistance 
was requested when the first hypersensitivity reaction was im-
mediate and life threatening.
dia-specific IgE antibodies have seldom been detected (8). How-
ever, during the last few years, several investigators have reported 
positive skin tests in patients with both IRs and NIRs, support-
ing an underlying allergic mechanism (9). In particular, it has 
been proposed that IRs may be elicited both by IgE-mediated 
mechanisms and by ICM direct induced histamine release from 
basophils and mast cells (9-11). On the contrary, most NIRs ap-
pear to be T-cell mediated, as suggested by the presence of der-
mal infiltrates of T cells in affected skin and by the proliferative 
T cell responses to the culprit ICM in vitro (4,12-14). Based on 
these immunological evidences, skin tests with diagnostic pur-
poses have gained new consideration in recent years, and several 
studies addressed the role of skin prick tests (SPTs), intradermal 
tests (IDTs) and patch tests (PTs) in identifying hypersensitiv-
ity to ICM. In particular, the first “European multicenter skin 
test study” showed that up to 50% of patients with previous 
IRs and NIRs could be diagnosed by standardized skin tests, 
if evaluated within 2-6 months after the index reaction (15). 
However, despite these evidences, hypersensitivity to ICM still 
represents a major concern in clinical settings where repeated 
radiological examinations are required, as in case of malignant 
and chronic inflammatory disorders. In effect, the prognostic 
value of skin tests for the selection of safe alternative ICM in pa-
tients with previous adverse reactions to iodinated compounds 
remains poorly characterized. Moreover, the various published 
premedication protocols are not protective in cases of previous 
severe anaphylaxis, and do not completely guarantee patients 
against recurrent adverse reactions (16-19). In this sense, a large 
meta-analysis concluded that physicians should not completely 
rely on the efficacy of premedication alone since, in unselected 
patients, a large number of subjects need to be premedicated to 
prevent one potentially serious reaction (19). 
Given these areas of uncertainty, in the present work we propose 
an algorithm that combines and integrates clinical history, skin 
tests performed according to international guidelines and pre-
medication, for preventing recurrent hypersensitivity reactions 
to ICM. 
Materials and methods
Patients. From our Database of Hypersensitivity reactions to 
ICM, we identified 36 consecutive patients who were tested 
within 2 to 6 months after the adverse reaction, in accordance 
with the timing indicated by international guidelines (15). Pa-
tients included in this study were referred between March 2010 
and January 2014. Hypersensitivity reactions were classified as 
IRs when occurring within one hour after ICM injection, and 
as NIRs when occurring from one hour to 7 days after ICM 
administration (4). Immediate reactions were graded according 
to the Ring and Messmer classification: generalized cutaneous 
and/or mucocutaneous symptoms like pruritus, skin eruption, 
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Iodinated Contrast Media: ICM, Skin Prick tests: SPTs, Intra-
dermal tests: IDTs, Patch tests: PTs, Immediate reaction: IR. 
Results
Clinical characteristics of the patients’ cohort
Thirty-six patients (mean age 58 years; range 22-75) (9 males 
and 27 females) were included in this study. Their clinical char-
acteristics are summarized in table 1 and 2. Nineteen subjects 
(mean age 58 years; range 22-75) experienced an IR; seventeen 
patients (mean age 57 years; range 35-75) had a NIR. The over-
all male:female ratio was 1:3, with an increased incidence of 
both IRs and NIRs among females. Adverse reactions of both 
immediate and non-immediate type were related to computed 
tomography (CT) scan in the majority of cases. The remaining 
cases of adverse reactions occurred during angiography (two cas-
es of Irs and one case of NIR) and urography (one case of IR). 
The culprit ICM was known in 27/36 cases (75%) (14 cases of 
Irs and 13 cases of NIRs) and unknown in 9/36 cases (25%) 
(5 cases of Irs and 4 cases of NIRs): Iopromide was the most 
frequently involved ICM both in Irs and NIRs. 
An allergic background was present in 6/19 patients (32%) who 
experienced an IR and 7/17 patients (41%) with a previous 
NIR. Drug hypersensitivity represented the most frequently re-
ported past allergic manifestation in both groups, followed by 
rhino-conjunctivitis and allergic contact dermatitis. Sixty-eight 
percent and 59% of subjects with immediate and non-immedi-
ate reactions, respectively, were not allergic. Seventy-five percent 
of the patients who experienced an adverse reaction to ICM in 
our cohort (14/19 patients with previous Irs and 13/17 with 
NIRs) had an underlying oncological disease and required peri-
odical follow-up radiological exams. 
Table 2 summarizes clinical manifestations of Irs and NIRs to 
ICM in the patients’ cohort. Immediate reactions consisted of 
12 grade 1, 3 grade 2 and 4 grade 3 reactions; NIRs were mild 
and moderate in 16 and 1 cases, respectively. Mucocutaneous 
involvement was the presenting feature in 95% of Irs and 100% 
of NIRs. Respiratory symptoms manifested only as part of an 
IR in 37% of patients. Gastrointestinal and neurological in-
volvement accounted for a minor proportion of allergic mani-
festations. Four subjects (11%) experienced anaphylactic shock 
requiring epinephrine injection. 
Skin testing
Skin tests were performed on average 16 weeks (range 8-25) af-
ter the reaction, and results are reported in table 3 and 4. SPTs 
were negative in all patients. IDTs were positive in 7/19 patients 
with a previous IR and 4/17 patients with a previous NIR. In 
Follow-up. After ICM re-exposure, patients were monitored for 
one hour and discharged if no IRs occurred. Patients were then 
instructed to report any type of NIR occurring in the following 
7 days, and to take pictures of eventual non-immediate skin 
eruptions; moreover, in case of adverse events occurring in this 
time frame, patients were immediately evaluated at our Insti-
tutes. Finally, patients were called a week after ICM injection 
and asked for possible hypersensitivity reactions, clinical condi-
tions and drug assumption (mainly corticosteroids and/or anti-
histamines) in the previous 7 days.
Statistics. Statistical analysis was performed using GraphPad 
Prism software 6.0. Continuous variables are expressed as mean 
(range minimum-maximum value), unless otherwise specified.
Figure 1 - Algorithm for the selection of an alternative ICM. 
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When known, the culprit ICM elicited a positive skin test in 
5/14 cases of IRs, and 2/13 cases of NIRs. 
Re-exposure to iodinated contrast media
All patients underwent a new contrast enhanced radiological pro-
cedure. Patients with previous IRs and NIRs were re-exposed to 
the alternative ICM on average 8 months (range 1-12 months) 
and 5 months (range 1 week-21 months), respectively, after the 
index adverse event (table 3 and 4). All patient were premedicat-
ed, and ICM dosage was not adapted because of the past clini-
cal history of adverse reaction. 18/19 patients with previous IRs 
(95%) and 17/17 patients with previous NIRs (100%) tolerated 
the group of patients who experienced an IR, IDTs were posi-
tive in 2 cases with ICM diluted 1:100, 4 cases with ICM dilut-
ed 1:10, and 2 cases with ICM diluted 1:1; 6 subjects developed 
a skin reaction at 20 minutes (immediate reading) and 2 at 48 
hours (delayed reading). In the group of patients who experi-
enced an NIR, IDTs were positive in 4 cases with ICM diluted 
1:10; two subjects developed a skin reaction at 20 minutes and 
2 at 48 hours. PTs were positive at 48 hours in one patient with 
a previous NIR. The rate of positive skin tests in our cohort 
was 7/19 (37%) in the group of patients with a previous IR and 
5/17 (30%) in the group of patients with a previous NIR. The 
overall rate of positive skin tests in our cohort was 12/36 (33%). 
Table 1 - Clinical characteristics of the patients’ cohort.
Immediate  Reactions Non-immediate  
Reactions
Total
Number of Patients 19 17 36
Female, n (%) 14 (74%) 13 (76%) 27 (75%)
Age, mean (range) 58 (22-75) 57 (35-75) 58 (22-75)
Allergic history, n (%) 6 (32%) 7 (41%) 13 (36%)
Rhinoconjunctivitis 3 2 5 
Drug allergies 4 2 6
Allergic contact dermatitis 2 1 3
         Food allergy  1 1
Hymenoptera venom allergy 1 1
Not allergic, n (%) 13 (68%) 10 (59%) 23 (64%)
Ongoing disease requiring ICM exam, n (%)
Oncological disease 14 13  27 (75%)
Chronic pulmonary disease 2  2 (5%)
Cardiovascular disease 1 4  5 (14%)
Autoimmune disease 1  1 (3%)
Other 1  1 (3%)
Implicated contrast medium, n
Iomeprol (non-ionic monomer) 2 2 4 (11%)
Iopamidol (non-ionic monomer) 1  1 (3%)
Iopromide (non-ionic monomer) 8 6 14 (39%)
Iodixanol (non-ionic dimer) 3 5 8 (22%)
Unknown 5 4 9 (25%)
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diagnostic and interventional procedures (2). However, our 
knowledge about the implicated allergic and non-allergic mech-
anisms has not grown in parallel and clinicians actually lack ac-
curate techniques for the diagnosis of hypersensitivity to ICM. 
Moreover, the introduction of nonionic low-osmolar products 
drastically reduced life-threatening reactions but did not pre-
vent them, and anaphylaxis still remains a major concern both 
for patients and radiologists. This is particularly true for clinical 
conditions where repeated ICM injections are required for eval-
uation or follow-up, as in case of neoplastic, cardiovascular or 
chronic inflammatory disorders. Indeed, in these common clin-
ical settings, allergists are oftentimes asked to readily provide an 
the alternative ICM selected according to the previously cited 
criteria, reported in the algorithm in figure 1. A single patient, 
who had a previous grade 1 IR to an unknown ICM, developed 
a self-limited localized slightly itchy erythema 48 hours after 
exposure to iobitridol. Notably, according to our algorithm, a 
non-ionic dimeric ICM would have been the alternative of choice 
in this case; however, non-ionic dimers were not available when 
skin tests were performed and were, therefore, not tested. 
Discussion
The incidence of hypersensitivity reactions to ICM has in-
creased along with the large use of these compounds for both 
Table 2 - Adverse reactions to ICM: severity of the reaction and clinical manifestations.
Immediate  Reactions 
n = 19
Non-immediate Reactions 
n = 17
Total
n = 36
Severity of the reaction
Grade I 12
Grade II 3
Grade III 4
Grade IV
Mild 16
Moderate 1
Severe
Mucocutaneous involvement, n (%) 18 (95%) 17  (100%) 35 (97%)
Urticaria 6 6
Mucocutaneous Angioedema 6
Exanthema 1 11
Erythema 4
         Conjunctivitis 1
Respiratory involvement, n (%)  7 (37%) 7 (19%)
Rhinitis 2
Dispnea 1
Bronchospasm 1
Laryngeal edema 3
Gastrointestinal involvement, n (%)   2 (12%) 2 (5%)
Nausea/vomiting 2
Neurological involvement, n (%) 1  (5%) 1 (3%)
Paresthesia 1
Anaphylactic Shock*, n (%)  4 (21%) 4 (11%)
*Anaphylactic Shock was defined according to international Consensus statements23.
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peated reactions to ICM decreased from 17-30% to 11% by us-
ing a corticosteroid and antihistamine preparation, but were not 
abolished (18). In other words, premedication alone has been 
proven to be insufficient for a complete prevention of recurrent 
reactions to ICM, and we are actually unable to predict those 
patients that will react despite pretreatment. 
International guidelines also suggest avoidance of the culprit 
ICM as an additional preventive measure (4), but the causative 
alternative ICM, because radiological exams need to be repeated 
every 6 to 12 months. 
For these reasons, premedication actually represents the most 
widely adopted measure for preventing recurrent hypersensitivi-
ty reactions to ICM. However, several works demonstrated that 
current premedication procedures appear to reduce symptoms, 
but may not prevent repeated reactions (16-19). Moreover, 
studies performed by Greenberger and colleagues found that re-
Table 3 - Outcomes of patients with previous IRs re-exposed to alternative ICM.
Pt. Radiological 
procedure
Type of IR Culprit ICM Skin test results1 Alternative 
ICM
Months 
after reaction
Outcome
1 CT scan Grade 1 Iodixanol IDT 1:10 Iodixanol 
at 48 hrs
Iopromide 3 No reactions
2 CT scan Grade 1 Unknown Negative Iodixanol 4 No reactions
3 CT scan Grade 1 Unknown Negative Iodixanol 7 No reactions
4 Urography Grade 1 Unknown Negative Iodixanol 6 No reactions
5 CT scan Grade 1 Unknown Negative Iobitridol 11 NIR (Mild)
6 CT scan Grade 1 Iomeprol Negative Iodixanol 5 No reactions
7 CT scan Grade 1 Iopromide Negative Iodixanol 9 No reactions
8 CT scan Grade 1 Iopromide IDT 1:100 Iopro-
mide
Iodixanol 2 No reactions
9 CT scan Grade 1 Iopromide IDT 1:10 
Iopromide and 1:1 
Iomeprol. IDT 1:1 
iomeprol at 48hrs
Iodixanol 6 No reactions
10 CT scan Grade 1 Iopromide Negative Iodixanol 3 No reactions
11 CT scan Grade 1 Iodixanol IDT 1:1 Iopromide Iomeprol 1 No reactions
12 CT scan Grade 2 Iopromide Negative Iodixanol 7 No reactions
13 CT scan Grade 3 Iopromide Negative Iodixanol2 9 No reactions
14 CT scan Grade 3 Iopamidol Negative Iodixanol2 7 No reactions
15 CT scan Grade 3 Iodixanol Negative Iopromide2 6 No reactions
16 CT scan Grade 3 Iomeprol IDT 1:10 Iomeprol 
and Iopromide 
Iodixanol2 2 No reactions
17 Angiography Grade 3 Unknown IDT 1:10 
Iopromide
 Iodixanol2 12 No reactions
18 Angiography Grade 3 Iopromide Negative  Iodixanol2 9 No reactions
19 CT scan Grade 3 Iopromide IDT 1:100 Iopro-
mide
 Iodixanol2 10 No reactions
1Skin tests included IDTs and PTs: only positive results are reported. 
2ICU doctor assistance was requested in presence of a history of severe IR to a previous ICM. All patients underwent premedication before 
re-exposure to the alternative ICM. 
Computed tomography: CT; Iodinated contrast medium: ICM; Immediate reaction: IR; Intradermal test: IDT.
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interval between the reaction and skin tests (11.5 years). In ef-
fect, since avoidance of the culprit ICM reduces the likelihood 
of a second hypersensitivity reaction, awareness of the impli-
cated substance should integrate skin tests’ results for deciding 
which alternative compounds to inject. On the other hand, skin 
tests with ICM should be performed from 2 to 6 months after 
the reaction in order to obtain the highest sensitivity (4,15). At 
later time points, in fact, loss of sensitization is known to sig-
nificantly decrease the frequency of positive responses (15,27). 
Moreover, the negative predictive value of skin tests with ICM 
was calculated by analyzing immediate and non-immediate re-
actions together, although differences in terms of pathogenic 
mechanisms between the two types of reactions are well known 
in the literature (9-14). 
All in all, standardized guidelines for preventing recurrent ad-
verse reactions to ICM are lacking, adequate tools for the selec-
tion of safe alternative iodinated compounds need to be refined, 
iodinated compound is still rarely reported by radiologists and, 
thus, typically ignored in everyday clinical practice.
Thus, different approaches have been evaluated in order to iden-
tify safe alternative ICM. For instance, drug provocation test was 
reported to reliably diagnose NIRs to ICM, and was proposed 
as an additional tool for identifying alternative compounds, al-
though reasonable safety concerns still remain to be complete-
ly addressed (24,25). Similarly, a large European multicentric 
study reported high specificity of skin tests in the diagnosis of 
immediate and non-immediate ICM reactions, but their useful-
ness in the selection of alternative and safe compounds was not 
evaluated (15). In trying to address this issue, a recent pivotal 
study reported a negative predictive value for ICM skin tests 
of 97%; of note, patients in this series were not premedicated 
before re-exposure to ICM (26). However, this promising result 
has to be interpreted in light of two main limits: (i) the absence 
of reports about the culprit ICM, and (ii) the long median time 
Table 4 - Outcomes of patients with previous NIRs re-exposed to alternative ICM.
Pt. Radiological  
procedure
Type of NIR Culprit ICM Skin test results1 Alternative 
ICM
Months after 
reaction
Outcome
1 CT scan Mild Iodixanol Negative Iopromide 2 No reactions
2 CT scan Mild Iomeprol Negative Iodixanol 7 No reactions
3 CT scan Mild Unknown Negative Iodixanol 9 No reactions
4 CT scan Mild Iopromide Negative Iodixanol 6 No reactions
5 CT scan Mild Iopromide Negative Iodixanol 3 No reactions
6 CT scan Mild Iopromide IDT Iomeprol, 
Iodixanol, Iopromide 
1:10 at 48 hrs
Iohexol 21 No reactions
7 CT scan Mild Iodixanol IDT 1:10 Iodixanol 
at 48 hrs
Iopromide 8 No reactions
8 CT scan Mild Unknown PT Iohexol at 48 hrs Iodixanol 5 No reactions
9 Angiography Mild Iodixanol Negative 6 No reactions
10 CT scan Mild Iodixanol Negative Iopromide 3 weeks No reactions
11 CT scan Mild Iopromide Negative Iodixanol 4 No reactions
12 CT scan Mild Iopromide Negative Iodixanol 1 week No reactions
13 CT scan Mild Iopromide Negative Iodixanol 2 weeks No reactions
14 CT scan Mild Iodixanol Negative Iopromide 1 No reactions
15 CT scan Moderate Unknown IDT 1:10 Iopromide Iodixanol 7 No reactions
16 CT scan Moderate Unknown IDT 1:10 Iopromide Iodixanol 4 No reactions
17 CT scan Moderate Iomeprol Negative Iodixanol 8 No reactions
1Skin tests included IDTs and PTs: only positive results are reported. All patients underwent premedication before re-exposure to the alternative ICM. 
Computed tomography: CT; Iodinated contrast medium: ICM; Non-immediate reaction: NIR; Intradermal test: IDT; Patch test: PT.
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compounds. Indeed, cross-reactivity between different ICM is 
a clinically important problem and a well-defined phenomenon 
that primarily resides in the presence of contrast media-specific 
T cells (14). In this sense, skin tests might have been of further 
help in identifying potentially additional harmful ICM for in-
dividual patients. 
Dissecting the protective contribution of premedication as well 
as the negative predictive value of skin tests is far beyond the 
purposes of the present study, but the reported results are in 
accordance with those of the literature and support the notion 
that premedication alone is not sufficient to control further re-
actions to ICM. Rather, the identification of a safe alternative 
ICM appears to be equally important for reducing the likeli-
hood of a new hypersensitivity reaction.
Conclusions
In conclusion, we herein provide clinicians with a practical al-
gorithm for approaching patients who need to be re-exposed to 
ICM despite a history of immediate or non-immediate hyper-
sensitivity reactions to iodinated compounds. In particular, given 
the lack of established guidelines for the management of these 
subjects, the proposed algorithm represents a reliable and easily 
replicable tool for safely re-exposing patients to ICM in clinical 
settings where repeated radiological examinations are required. 
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and premedication alone does not offer complete protection to 
patients with hypersensitivity to these substances. 
In the present work, we validated an algorithm that efficient-
ly protected 95% of patients with a previous IR and 100% of 
patients with a previous NIR from recurrent reactions to ICM. 
The algorithm was based on (i) the avoidance of the culprit 
ICM (when known in the majority of cases), (ii) the selection 
of an alternative ICM by integrating clinical history and skin 
tests results, and (iii) the premedication of all patients. Of note, 
all patients underwent skin tests within 2 to 6 months after the 
index adverse reaction, in accordance with the international 
guidelines (4,15). 
Thanks to this approach, we were able to safely re-expose all 
patients to ICM early after the index adverse event, because the 
vast majority of subjects in our cohort had clinical priorities 
related to follow-up of oncological or chronic inflammatory 
diseases. The algorithm was equally efficacious both in case of 
a previous immediate and non-immediate adverse reaction to 
ICM. In particular, the combined use of SPTs, immediate and 
delayed reading IDTs and PTs, guided the selection of an alter-
native compound, both in case of positive and negative result. 
In fact, positive skin tests identified ICM that were avoided in 
subsequent radiological exams, while negative skin tests identi-
fied potentially safe ICM, unless involved in the previous ad-
verse reaction. The knowledge of the culprit ICM was, there-
fore, crucial in the algorithm, since that substance was avoided 
in the following radiological procedures. Hence, radiologists are 
strongly encouraged to record the name of the injected iodin-
ated compound, especially if patients need to undergo repeated 
exams. In light of these considerations, it is reasonable to think 
that the false negative patient had, indeed, a second adverse re-
action to the same ICM, because the initial culprit ICM was 
unknown. 
Moreover, it is noteworthy to observe that the proportion of pa-
tients who tolerated the alternative ICM (95% of patients with 
a previous IR and 100% of those with a previous NIR) was very 
similar to what reported by Caimmi without premedication. Of 
course, it is possible that premedication might have suppressed 
part of minor reactions in our cohort of patients. Alternatively, 
since both immediate and non-immediate reactions are known 
to occur despite pretreatment with corticosteroids and antihis-
tamines, we might speculate that the selection of the alternative 
ICM, rather than premedication, played a major role in pre-
venting recurrent hypersensitivity reactions. A third additional 
and comprehensive hypothesis is that both the selection of an 
alternative ICM and premedication concurred in efficaciously 
protecting patients from a subsequent adverse reaction. 
Finally, the presence of positive skin tests results for ICM oth-
er than the culprit ones, might indicate either a real multiple 
sensitization, or cross-reactivity between different iodinated 
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